R1 Therapeutics
R1 Therapeutics is a clinical-stage biopharmaceutical company developing a first-in-class therapy for hyperphosphatemia in patients with chronic kidney disease. Its lead program, AP306, is a differentiated pan phosphate transporter inhibitor designed to block active phosphate transport in the gut, potentially offering more effective phosphate lowering with a lower pill burden than existing therapies. R1 is advancing AP306 globally into Phase 2b development to address a major unmet need in dialysis-dependent CKD.
